Related Experiment Video

Updated: Sep 28, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.0K

Sickle Cell Drug Approved for Children Ages Four to 11

Diane S Aschenbrenner1

  • 1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch:diane.aschenbrenner@gmail.com .

The American Journal of Nursing
|March 29, 2022
PubMed

Insights

Voxelotor (Oxbryta) is now approved for children aged 4-11 with sickle cell disease. This medication prevents red blood cell sickling, reducing organ damage in this vulnerable population.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin.
  • Red blood cells (RBCs) in SCD patients adopt a rigid, sickle shape, leading to vaso-occlusion and end-organ damage.
  • Current treatments for SCD aim to manage symptoms and prevent complications.

Purpose of the Study:

  • To report the accelerated approval of voxelotor (Oxbryta) for treating sickle cell disease in children aged 4 to 11 years.
  • To highlight the new indication for voxelotor, expanding its therapeutic use.
  • To underscore the mechanism of action of voxelotor in addressing the underlying pathophysiology of SCD.

Main Methods:

  • This is an informational abstract regarding a new drug indication.
  • The abstract summarizes the drug's mechanism and approved patient population.
  • No specific clinical trial data is presented in this abstract.

Main Results:

  • Voxelotor (Oxbryta) has received accelerated approval from regulatory authorities.
  • The approval is for the treatment of sickle cell disease in pediatric patients aged 4 to 11 years.
  • This represents a new indication for the previously approved drug.

Conclusions:

  • Voxelotor offers a novel therapeutic option for children with sickle cell disease.
  • By inhibiting RBC sickling, voxelotor aims to reduce disease-related complications.
  • The expanded indication provides a treatment targeting the pathophysiology of sickle cell disease in younger patients.

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.7K

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
875
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
274
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
527
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
270